CN109824584A - A kind of class peptides and its preparation method and application containing Terleu - Google Patents
A kind of class peptides and its preparation method and application containing Terleu Download PDFInfo
- Publication number
- CN109824584A CN109824584A CN201910049053.5A CN201910049053A CN109824584A CN 109824584 A CN109824584 A CN 109824584A CN 201910049053 A CN201910049053 A CN 201910049053A CN 109824584 A CN109824584 A CN 109824584A
- Authority
- CN
- China
- Prior art keywords
- terleu
- bromo
- chloro
- class peptides
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
A kind of class peptides and its preparation method and application containing Terleu, utilize acylation, Suzuki coupling, the reaction synthesising target compound such as condensation, and construct compound library, such compound is the Bcr-Abl small molecule tyrosine kinase inhibitors with new molecular architecture, the present invention uses the drug design strategies based on segment, using biphenyl pyridine as hinge area binding fragment, introducing S-Leucine is flexibility Linker, to construct the class peptides small molecule compound library with kinase inhibiting activity, and the tyrosine kinase inhibitor of Bcr-Abl kinase inhibiting activity is found to have by the screening of the kinase activity of ADP-Glo.Kinases screening test shows that such compound all has certain inhibitory activity to Abl kinases, T315I mutation Abl kinases, and cell proliferation test shows that majority of compounds has certain inhibitory activity to K562 cell.
Description
Technical field
The present invention relates to a kind of class peptides and its preparation method and application containing Terleu.
Background technique
Chronic myelocytic leukemia (CML) is a kind of malignant clone proliferative disease for betiding marrow hemopoietic stem cells,
Proportion is up to 15%~20% in adult leukaemic, it is characterized in that CML patient's body can detect Ph chromosome.
Ph chromosome is the breaking point aggregation cluster-Ai Erbei formed by No. 22 chromosomes and No. 9 chromosome reciprocal translocations of human normal
Inferior (BCR-ABL) fusion, the Bcr-Abl that this fusion coding generates tyrosine kinase activity sustained activation merge egg
It is white.Have listed currently on the market for Bcr-Abl be target small molecule tyrosine kinase inhibitors, but all exist drug resistance with
And the problems such as other clinical adverses.Therewith, the novel Bcr-Abl tyrosine kinase inhibitor of research and development has become medicine
One of the hot spot in field.
Summary of the invention
The purpose of the present invention is to provide a kind of class peptides and its preparation method and application containing Terleu.
To achieve the above object, the present invention adopts the following technical scheme that:
A kind of class peptides containing Terleu, the structural formula of such compound are as follows:
Wherein, R is
A kind of preparation method of the class peptides containing Terleu, comprising the following steps:
1) the acylated bromo- 2-aminopyridine of 5- of acylation reaction preparation occurs for the bromo- 2-aminopyridine of 5- and chloride compounds；
2)N2Under protection, 5- bromo-nicotinic acid, thionyl chloride and aminated compounds, which react, prepares the 5- bromo-nicotinic acid of ammonification；
3) under tetra-triphenylphosphine palladium catalysis, the 5- bromo-nicotinic acid and right/carboxylic of the bromo- 2-aminopyridine of acylated 5- or ammonification
Suzuki coupling reaction occurs for base phenyl boric acid, obtains biphenol compound；
4) Fmoc-L- Terleu and the chloro- 3- 5-trifluoromethylaniline condensation of 4- generate (9 fluorenes -9- base) methyl (S)-(1-
((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate；
5) (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxygen
For butyl- 2- yl) t-butyl carbamate take off Fmoc protecting group generate (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -
3,3- amide dimethyl butyrate；
6) biphenol compound and (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate are condensed
Generate the class peptides containing Terleu.
A further improvement of the present invention lies in that the step 1) detailed process are as follows: the bromo- 2-aminopyridine of 5- is dissolved in nothing
In water methylene chloride, triethylamine is added, under condition of ice bath, chloride compounds is added dropwise and removes ice bath after being added dropwise and rises to
After reacting at room temperature 12h, is post-processed, obtain the bromo- 2-aminopyridine of acylated 5-.
A further improvement of the present invention lies in that the step 2) detailed process are as follows: in N2Under protection, thionyl chloride is dripped
It is added in 5- bromo-nicotinic acid, after dripping, is heated to reflux 2-3h and is clarified to solution, decompression rotation removes thionyl chloride, obtains faint yellow
The faint yellow solid is added in anhydrous methylene chloride by solid, and the two of aminated compounds is then added drop-wise under condition of ice bath
In chloromethanes solution；After dripping, it is warmed to room temperature reaction 12h and is post-processed after reaction, obtain the bromo- cigarette of 5- of ammonification
Acid.
A further improvement of the present invention lies in that the step 3) detailed process are as follows: by the acylated bromo- 2-aminopyridine of 5-
It is added in reaction vessel with right/Carboxybenzeneboronic acid, or the bromo- niacin of the 5- of ammonification and right/Carboxybenzeneboronic acid is added to
In reaction vessel, cesium carbonate and tetra-triphenylphosphine palladium are sequentially added；Then the mixed solution of acetonitrile and water, N are added2It protects
Shield, is warming up to 90 DEG C of reaction 48h；After reaction, it is post-processed, obtains biphenol compound.
A further improvement of the present invention lies in that the detailed process of the step 4) are as follows: by the chloro- 3- 5-trifluoromethylaniline of 4-,
HOBT, HATU are dissolved in anhydrous methylene chloride, and DIPEA is then added dropwise, and after being added dropwise, Fmoc-L- Terleu is added dropwise
Dichloromethane solution reacts at room temperature 5h, is post-processed, obtain (9 fluorenes -9- base) methyl (S)-(1- ((chloro- 3- (fluoroform of 4-
Base) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate.
A further improvement of the present invention lies in that the detailed process of the step 5) are as follows: at 0 DEG C, by (9 fluorenes -9- base) methyl
(S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate
It is dissolved in anhydrous methylene chloride, the DMF solution of 20% piperidines of volumetric concentration is then added dropwise, after reacting 1h, post-processed, obtained
(S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate.
A further improvement of the present invention lies in that the detailed process of the step 6) are as follows: biphenol compound, PyBOP to be dissolved in
In anhydrous DMF, DIPEA is added dropwise, after reacting at room temperature 5min, (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3 is added,
3- amide dimethyl butyrate reacts at room temperature 12h, is post-processed, obtain the class peptides containing Terleu.
A kind of class peptides containing Terleu, such compound is in preparation for inhibiting Abl kinases, T315I
The application being mutated in Abl kinase activity drug.
A kind of class peptides containing Terleu, such peptides answering in the preparation of antitumor drugs
With.
Compared with prior art, the invention has the benefit that the present invention utilizes acylated, Suzuki coupling, condensation etc.
Synthesising target compound is reacted, and constructs compound library, such compound is that have small point of the Bcr-Abl of new molecular architecture
Sub- tyrosine kinase inhibitor, and characterize by means such as MS, NMR the structure of target compound.The present invention, which uses, is based on piece
The drug design strategies of section, using biphenyl pyridine as hinge area binding fragment, introducing S-Leucine is flexibility Linker, with building
Class peptides small molecule compound library with kinase inhibiting activity, and be found to have by the screening of the kinase activity of ADP-Glo
The tyrosine kinase inhibitor of Bcr-Abl kinase inhibiting activity.Kinases screening test show such compound to Abl kinases,
T315I mutation Abl kinases all has certain inhibitory activity, and wherein R isWhen to T315I mutation Abl kinases activity
Most preferably.Cell proliferation test shows that majority of compounds has certain inhibitory activity to K562 cell.Structure-activity analysis hair
Existing: the spatial match for introducing the derivative of S-Leucine and the site ATP of Abl kinases is good, binding mode and referring to small point
Sub- Imatinib is consistent, illustrates that the introducing of S-Leucine plays a significant role the inhibitory activity of compound.On pyridine ring
Amide side chains are introduced to improve the affinity of small molecule and receptor, can be used as and press down by the tyrosine kinase of target of Bcr-Abl
The novel drug effect segment of system.
Detailed description of the invention
Fig. 1 is synthetic route chart of the invention.
Specific embodiment
The present invention is described in detail with reference to the accompanying drawing.
Referring to Fig. 1, a kind of structural formula of class peptides containing Terleu of the invention are as follows:
Wherein, R is specific as follows, is shown in Table 1:
Group representated by table 1R
It is illustrated below by specific embodiment.
Referring to Fig. 1, the preparation method of the class peptides containing Terleu of above structure, comprising the following steps:
1) with corresponding chloride compounds the acylated bromo- 2- amino of 5- of acylation reaction preparation occurs for the bromo- 2-aminopyridine of 5-
Pyridine；
Step 1) the detailed process are as follows: the bromo- 2-aminopyridine of 5- is dissolved in anhydrous methylene chloride, three second are added
Corresponding chloride compounds are slowly dropped in above-mentioned solution by amine under condition of ice bath, after being added dropwise, remove ice bath
It is warmed to room temperature reaction 12h.After reaction, methylene chloride dilution, washing is added, saturated sodium bicarbonate water is washed, saturated sodium-chloride
Washing, anhydrous sodium sulfate is dry, and vacuum distillation, pillar layer separation obtains white solid, the bromo- 2- amino of the 5- being as acylated
Pyridine.
2)N2Under protection, 5- bromo-nicotinic acid reacts with thionyl chloride and corresponding aminated compounds and prepares the 5- of ammonification
Bromo-nicotinic acid；
Step 2) the detailed process are as follows: in N2Under protection, thionyl chloride is added dropwise in 5- bromo-nicotinic acid, is dripped
Afterwards, it is heated to reflux 2-3h to clarify to solution, decompression rotation removes thionyl chloride, obtains faint yellow solid, which is dissolved in
The two of corresponding aminated compounds is slowly dropped under condition of ice bath into anhydrous methylene chloride, and by this reactive intermediate solution
In chloromethanes solution；After dripping, it is warmed to room temperature reaction 12h and K is added into reaction system after reaction2CO3Solution, point
Liquid takes methylene chloride phase, and water phase is extracted with dichloromethane, and merges organic phase, anhydrous Na2SO4It is dry；Column chromatography separating purification obtains
White solid, as by the bromo- niacin of the 5- of ammonification.
3) under tetra-triphenylphosphine palladium catalysis, the 5- bromo-nicotinic acid and right/carboxylic of the bromo- 2-aminopyridine of acylated 5- or ammonification
Suzuki coupling reaction occurs for base phenyl boric acid, obtains biphenol compound；
Step 3) the detailed process are as follows: be added to the acylated bromo- 2-aminopyridine of 5- and right/Carboxybenzeneboronic acid
In pear shape bottle, or the bromo- niacin of the 5- of ammonification and right/Carboxybenzeneboronic acid is added in pear shape bottle, sequentially adds cesium carbonate
With tetra-triphenylphosphine palladium；The mixed solution of acetonitrile/water, N are added into said mixture2Protection, oil bath are warming up to 90 DEG C of reactions
48h；After reaction, reaction solution is down to room temperature, filtered.It is 4 that filtrate, which is adjusted to pH value with hydrochloric acid, and white solid is precipitated, filters,
Filter cake is dried in vacuo to obtain product, as biphenol compound.
4) Fmoc-L- Terleu and the chloro- 3- 5-trifluoromethylaniline condensation of 4- generate (9 fluorenes -9- base) methyl (S)-(1-
((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate；
Step 4) the detailed process are as follows: the chloro- 3- 5-trifluoromethylaniline of 4-, HOBT, HATU are dissolved in anhydrous methylene chloride
In, DIPEA is then added dropwise, after completion of dropwise addition, the Fmoc-L- Terleu solution for being dissolved in anhydrous methylene chloride is added dropwise.Room temperature is anti-
Answer 6h；After reaction, water is added to terminate reaction；Methylene chloride extraction merges organic phase, saturation NaCl washing, anhydrous Na SO4It is dry
Dry, pillar layer separation obtains (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- diformazan
Base -1- oxo butyl- 2- yl) t-butyl carbamate.
5) (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxygen
For butyl- 2- yl) t-butyl carbamate take off Fmoc protecting group generate (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -
3,3- amide dimethyl butyrate；
Step 5) the detailed process are as follows: (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) benzene will be obtained
Base) amino) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate is dissolved in anhydrous methylene chloride, at 0 DEG C, it is added dropwise
The DMF solution (volumetric concentration) of 20% piperidines, then reacts at room temperature 1h；After reaction, rotation removes solvent, and pillar layer separation obtains
To (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate.
6) biphenol compound and (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate are condensed
Generate the class peptides containing Terleu.
Step 6) the detailed process are as follows: biphenol compound, PyBOP are dissolved in anhydrous DMF, DIPEA solution, room is added dropwise
After temperature reaction 5min, (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate is added.Room temperature reaction
12h is post-processed, and the class peptides containing Terleu are obtained.
A kind of class peptides containing Terleu prepared such as the above method, such compound is for inhibiting
Application in Abl kinases, T315I mutation Abl kinase activity.
Such compound has antineoplastic action, can apply in the preparation of antitumor drugs.
Embodiment 1
A kind of class peptides containing Terleu, R areWhen, the preparation method is as follows:
1) synthesis of N- (5- bromopyridine -2- base) acetamide: the bromo- 2-aminopyridine of 5- (5.19g, 30mmol) is dissolved in
In 100ml anhydrous methylene chloride, triethylamine 20ml is added.Under condition of ice bath, chloroacetic chloride (2.54ml) is slowly dropped to
It states in solution, after dripping, removes ice bath, be warmed to room temperature reaction (i.e. reaction 12h) overnight.After reaction, dichloro is added
Methane dilution, is washed (30ml × 3), is saturated NaHCO3Solution is washed (30ml × 3), and saturation NaCl washes (30ml), and organic phase is anhydrous
Na2SO4It is dry.Pillar layer separation obtains white solid 5.65g, yield 88%.Mp 78-81℃；EI-MS(m/z):214[M]+。
2) synthesis of 4- (6- (acetylamino) pyridin-3-yl) benzoic acid: N- (5- bromopyridine -2- base) acetamide
(4.30g, 20mmol), Carboxybenzeneboronic acid (3.66g, 22mmol) is added in 250ml pear shape bottle, sequentially adds cesium carbonate
(13.0g, 40mmol), tetra-triphenylphosphine palladium (1.2g, 1mmol).Acetonitrile/water (V:V=3:2) is added into said mixture
200ml。N2Protection, oil bath are warming up to 90 DEG C of reaction 48h.After reaction, reaction solution is down to room temperature, filtered.Filtrate is used
It is 4 that 6mol/L hydrochloric acid, which is adjusted to pH value, and white solid is precipitated, and is filtered, and filter cake is dried in vacuo to obtain product 3.89g, yield 76%.Mp
156-158℃；EI-MS(m/z):256[M]+。
3) by the chloro- 3- 5-trifluoromethylaniline of 4- (0.49g, 2.5mmol), HOBT (0.69g, 4.2mmol), HATU (1.6g,
It 4.2mmol) is dissolved in the anhydrous methylene chloride of 30ml, DIPEA (1.43ml) then is added dropwise, after completion of dropwise addition, dropwise addition is dissolved in nothing
Fmoc-L- Terleu (1.0g, 2.8mmol) solution of water methylene chloride.React at room temperature 6h；After reaction, 20ml is added
Water terminates reaction；Methylene chloride extracts (3), merges organic phase, saturation NaCl washing, anhydrous Na SO4It is dry, pillar layer separation,
Obtain (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2-
Base) t-butyl carbamate 0.54g.Faint yellow oily solid, yield 36.2%.EI-MS(m/z):529.0[M]+。
4) (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- diformazan will be obtained
Base -1- oxo butyl- 2- yl) t-butyl carbamate (0.54g, 1.0mmol) is dissolved in anhydrous methylene chloride (20ml), at 0 DEG C,
The DMF solution (volumetric concentration) of 20% piperidines of 1ml is added dropwise, then reacts at room temperature 1h；After reaction, rotation removes solvent, column chromatography
It is solid to obtain (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl)-faint yellow oily of 3,3- amide dimethyl butyrate 0.34g for separation
Body.Yield 94.6%.EI-MS(m/z):337[M]+。
5) by 4- (6- (acetylamino) pyridin-3-yl) benzoic acid (0.1g, 3.9mmol), PyBOP (0.17g,
It 3.3mmol) is dissolved in anhydrous DMF (10ml), DIPEA (0.168ml) solution is added dropwise, after reacting at room temperature 5min, (S) -2- is added
Amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate (0.1g, 3.3mmol).12h is reacted at room temperature, is added
100ml water terminates reaction, and ethyl acetate (3 × 30ml) extraction merges organic phase, saturation NaCl washing, anhydrous Na SO4It is dry,
Pillar layer separation obtains (R) -4- (6- acetylamino pyridin-3-yl)-N- (1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -
3,3- dimethyl -1- oxygen butane -2- base) benzamide (B7).White powdery solids, yield 75%.EI-MS(m/z):
545.165[M]+；547.165[M]-.MP:57.6~59.9 DEG C；1H NMR(400MHz,DMSO)δ10.68(s,1H),8.67
(s, 2H), 8.27 (d, J=1.7Hz, 1H), 8.21 (d, J=8.7Hz, 1H), 7.99 (dd, J=27.1,8.2Hz, 2H), 7.89
(d, J=8.7Hz,
1H), 7.74 (d, J=8.2Hz, 2H), 7.69 (d, J=8.8Hz, 1H), 6.92 (s, 2H), 4.65 (t, J=
6.8Hz, 1H), 2.89 (s, 1H), 2.71 (d, J=17.8Hz, 1H), 1.08 (s, 9H), 0.87 (t, J=9.2Hz, 1H)
Embodiment 2
A kind of class peptides containing Terleu, R areWhen, the preparation method is as follows:
1) in N2Under protection, thionyl chloride (36ml, 494mmol) is added dropwise to 5- bromo-nicotinic acid (5.00g, 24.7mmol)
In, after dripping, it is heated to reflux 2-3h and is clarified to solution, decompression rotation removes thionyl chloride, obtains faint yellow solid.The solid is dissolved in
Cyclopropylamine is slowly dropped under condition of ice bath into 30ml anhydrous methylene chloride, and by this reactive intermediate solution
In (3.77ml) methylene chloride (30ml) solution.After dripping, it is warmed to room temperature reaction overnight.After reaction, to reaction system
Middle addition 2mol/L K2CO3Solution 20ml.Liquid separation takes methylene chloride phase, and water phase is extracted with dichloromethane (15ml × 3), is associated with
Machine phase, anhydrous Na2SO4It is dry.Column chromatography separating purification.(petroleum ether: ethyl acetate=1:1), obtains white solid 5.27g, yield
89%.Mp 140-142℃；EI-MS(m/z):240[M]+。
Step 2)~step 6) is same as Example 1, obtains compound B3, white solid, yield 28%；EI-MS(m/
z):571[M]+；573[M]-.MP:149~152.5 DEG C；1H NMR (400MHz, DMSO) δ 10.71 (s, 1H), 9.09 (d, J=
1.9Hz, 1H), 8.99 (d, J=1.7Hz, 1H), 8.79 (d, J=3.9Hz, 1H), 8.47 (s, 1H), 8.31 (dd, J=27.4,
5.5Hz, 2H), 8.05 (d, J=8.3Hz, 2H), 7.96-7.88 (m, 3H), 7.69 (d, J=8.8Hz, 1H), 4.66 (d, J=
8.7Hz, 1H), 2.90 (td, J=7.3,3.8Hz, 1H), 1.09 (s, 9H), 0.77-0.71 (m, 2H), 0.64-0.60 (m,
2H).
The same B3 of the synthesis step of B1, B2, B4.
Compound B-11, faint yellow solid, yield 54%.EI-MS(m/z):587[M]+；589[M]-.MP:97.6~99.7
℃；1H NMR (400MHz, DMSO) δ 10.70 (s, 1H), 9.05 (s, 1H), 8.62 (s, 1H), 8.31 (dd, J=30.2,
5.6Hz, 2H), 8.16 (s, 1H), 8.03 (d, J=8.4Hz, 2H), 7.90 (dd, J=11.8,5.4Hz, 3H), 7.69 (d, J=
8.8Hz, 1H), 4.66 (d, J=8.8Hz, 1H), 3.49 (d, J=6.9Hz, 2H), 3.24 (d, J=6.8Hz, 2H), 2.55-
2.48 (m, 2H), 1.20 (dd, J=13.3,6.4Hz, 4H), 1.09 (s, 9H)
Compound B2, white solid, yield 50%, EI-MS (m/z): 587 [M]+；589[M]-.MP:93.4~94.8 DEG C
；1H NMR (400MHz, DMSO) δ 10.74 (s, 1H), 9.08 (d, J=2.2Hz, 1H), 8.60 (d, J=1.9Hz, 1H), 8.56
(d, J=8.9Hz, 1H), 8.28 (d, J=2.5Hz, 1H), 8.21 (t, J=2.0Hz, 2H), 7.92 (ddd, J=12.5,
11.6,5.0Hz, 3H), 7.69 (d, J=8.8Hz, 1H), 7.62 (t, J=7.8Hz, 1H), 4.71 (d, J=8.9Hz, 1H),
3.49 (d, J=6.8Hz, 2H), 3.32-3.18 (m, 2H), 1.17 (dd, J=21.9,15.1Hz, 6H), 1.09 (s, 9H)
Compound B4, white solid, yield 54%, EI-MS (m/z): 571 [M]+；573[M]-.MP:138.2~140.6
℃；1H NMR (400MHz, DMSO) δ 10.74 (s, 1H), 9.14 (d, J=1.9Hz, 1H), 8.99 (d, J=1.7Hz, 1H),
8.78 (d, J=4.0Hz, 1H), 8.51 (dd, J=11.2,5.4Hz, 2H), 8.30-8.25 (m, 2H), 7.96 (dd, J=7.7,
6.1Hz, 2H), 7.90 (dd, J=8.8,2.2Hz, 1H), 7.71-7.61 (m, 2H), 4.71 (d, J=8.8Hz, 1H), 2.73
(s,1H),1.09(s,9H),0.80–0.71(m,2H),0.66–0.58(m,2H).
B5, B6, B8~B10 are identical with B7 synthesis step
Compound B5, white solid, yield 58%, EI-MS (m/z): 581 [M]+；583[M]-.MP:92.5~95.1 DEG C
；1H NMR (400MHz, DMSO) δ 10.69 (s, 1H), 8.27 (dd, J=5.5,3.1Hz, 2H), 8.14 (dd, J=8.7,
2.5Hz, 1H), 8.01 (s, 1H), 7.99 (s, 1H), 7.96 (s, 1H), 7.90 (dd, J=8.8,2.3Hz, 1H), 7.81 (s,
1H), 7.79 (s, 1H), 7.69 (d, J=8.8Hz, 1H), 7.10 (d, J=8.7Hz, 1H), 4.64 (d, J=8.8Hz, 1H),
3.01 (td, J=6.6,3.9Hz, 1H), 2.89 (s, 3H), 1.08 (d, J=4.6Hz, 9H)
Compound B-26, white solid, yield 58%, EI-MS (m/z): 581 [M]+；583[M]-.MP:67.3~69.4 DEG C
；1H NMR (400MHz, DMSO) δ 8.69 (d, J=2.3Hz, 1H), 8.39 (d, J=9.2Hz, 1H), 8.16 (dd, J=8.5,
2.4Hz, 2H), 7.85 (dd, J=10.0,8.7Hz, 2H), 7.57 (dd, J=10.2,5.3Hz, 1H), 7.10 (d, J=
8.6Hz, 1H), 5.05 (d, J=9.2Hz, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 1.60-1.56 (m, 2H), 1.40 (s,
1H), 1.04 (s, 9H), 0.95 (d, J=2.8Hz, 1H), 0.85 (ddd, J=6.6,5.7,2.4Hz, 2H)
Compound B8, white solid, yield 65%, EI-MS (m/z): 545 [M]+；547[M]-.MP:130.3~131.6
℃；1H NMR (400MHz, DMSO) δ 10.73 (s, 1H), 10.65 (s, 1H), 8.74 (s, 1H), 8.48 (d, J=8.8Hz,
1H), 8.28 (d, J=2.3Hz, 1H), 8.18 (d, J=12.7Hz, 3H), 7.89 (dd, J=12.3,5.1Hz, 3H), 7.69
(d, J=8.8Hz, 1H), 7.58 (t, J=7.8Hz, 1H), 4.70 (d, J=8.8Hz, 1H), 2.13 (s, 3H), 1.09 (s,
9H).
Compound B9, white solid, yield 65%, EI-MS (m/z): 587 [M]+；589[M]-.MP:57.6~59.9 DEG C
；1H NMR (400MHz, DMSO) δ 10.73 (s, 1H), 10.04-9.96 (m, 1H), 8.78-8.69 (m, 1H), 8.28 (dd, J=
5.6,3.1Hz, 2H), 8.18 (d, J=1.4Hz, 2H), 8.01 (d, J=8.4Hz, 2H), 7.90 (dd, J=8.8,2.4Hz,
1H), 7.84 (d, J=8.4Hz, 2H), 7.69 (d, J=8.8Hz, 1H), 4.66 (d, J=8.8Hz, 1H), 1.26 (s, 9H),
1.08(s,9H).
Compound B-11 0, white solid, yield 90%, EI-MS (m/z): 587 [M]+；589[M]-.MP:76.2~78.7
℃；1H NMR (400MHz, DMSO) δ 10.73 (s, 1H), 9.96 (s, 1H), 8.76-8.74 (m, 1H), 8.48 (d, J=
8.8Hz, 1H), 8.28 (d, J=2.5Hz, 1H), 8.20 (d, J=3.2Hz, 2H), 8.16 (s, 1H), 7.96 (s, 1H), 7.92-
7.87 (m, 3H), 7.68 (d, J=8.8Hz, 1H), 7.58 (t, J=7.8Hz, 1H), 4.70 (d, J=8.8Hz, 1H), 1.26
(s, 9H), 1.08 (d, J=7.0Hz, 9H)
Bcr-Abl kinase inhibition is carried out to the derivative of Terleu with anti-tumor activity produced by the present invention below
Screening active ingredients.
Measuring method is specific as follows:
Kinases ABL1, ABL (T315I) and substrate A bltide are purchased from Signal-Chem company, select Promega company
ADP-GloTMKinase Assays detection kit detects the Inhibiting enzyme activity of target compound, and operating method is said according to kit
Bright progress.
In Abl experiment, ATP (1mM) is used into buffer (2 ×) (Tris 80mM, MgCl2 20mM,BSA 0.2mg/ml,
DTT 2mM) dilute 80 times of buffer (2 ×) solution for being configured to ATP (125 μM)；125 μM of ATP solution and Abltide is molten
The mixed solution that liquid product 1:1 is hybridly prepared into ATP (62.5 μM)-Abltide (0.5 μ g/ μ l) is spare；ABL1 kinase solution is used
buffer(1×)(Tris 40mM,MgCl210mM, BSA 0.1mg/ml, DTT 1mM) dilution 100 times be configured to ABL1
Buffer (1 ×) solution for standby of (1ng/ μ l).
The preparation steps of ATP-Abltide and ABL1 (T315I) in Abl (T315I) experiment are same as above, unlike
ATP concentration is 12.5 μM, and the concentration of ABL1 (T315I) is 2ng/ μ l
Target compound and positive control drug (Imatinib) are configured to 6 × 10 with buffer (1 ×) respectively-6mol/L
Sample solution, sequentially add the mixed solution of 2 μ l ATP-Abltide, 1 μ l sample solution, 2 μ l enzymes in hole every on 384 orifice plates
Solution；Blank well adds the mixed solution of 3 μ l buffers and 2 μ l ATP-Abltide；Control wells add mixing for 2 μ l ATP-Abltide
Solution, 1 μ l buffer are closed, 2 μ l enzyme solutions finish, are incubated for 60min at 30 DEG C；5 μ l of ADP-Glo reagent is added, is incubated at 25 DEG C
Educate 40min；Kinase detection reagent is added, then is incubated for 30min at 25 DEG C.Using PerkinElmer multifunctional enzyme
The chemiluminescence module of mark instrument measures the luminous value in every hole, calculates compound to the inhibiting rate and IC of Abl50。
A kind of structural formula of class peptides containing Terleu of the invention are as follows:
Wherein, R is
The kinase inhibiting activity of the class peptides containing Terleu of structure above is as shown in table 2
Class peptides of the table 2 containing Terleu are to Bcr-Abl/Bcr-AblT315IInhibiting rate (%)
As can be seen from Table 2, most compound has inhibitory activity to Bcr-Abl kinases, to Bcr-AblT315
Kinases, majority of compounds have certain inhibitory activity, and inhibiting rate is in 53.4% to 98% range, part of compound
(B1, B3) reaches 90% or more to the inhibiting rate of T315I mutation Abl kinases, and activity is preferably.Activity Results show substituent group
Difference will have a direct impact on compound to the inhibitory activity of kinases.
The class peptides containing Terleu are measured below to the growth inhibitory activity of tumour cell.Using mtt assay
The class peptides containing Terleu are examined to act on the growth inhibitory activity of tumour cell.
Class peptides provided by the invention containing Terleu have antineoplastic action.Have to tumour cell
It is external to inhibit increment active effect, there is the increment activity effect for inhibiting tumour cell in human leukemia cell (K562 cell)
Fruit can be used for the treatment to leukaemia.
Human leukemia cell's (K562 cell) of logarithmic growth phase, is diluted to 10 with RPMI1640 culture medium4A/ml number
The cell solution of magnitude is inoculated in 96 well culture plates (2000-4000/hole) in parallel, and every hole inoculation volume is 180 μ l, and 37
DEG C, 5%CO212h is cultivated in incubator；
The 20 μ l of untested compound of various concentration is added in every hole, make the final concentration of of compound in hole: 1.5 × 10-5mol/
L, each concentration set 3 multiple holes, and compound is not added in negative control refinement born of the same parents, if 6 multiple holes, nilotinib or Imatinib are sun
Property control, continue cultivate 48h；
MTT (5mg/ml) 20 μ l is added in every hole, makes the final concentration 0.5mg/ml of MTT in hole, 37 DEG C of incubators are incubated for 4h, small
The heart, which is inhaled, abandons supernatant, and every hole adds 150 μ l of DMSO, vibrates 15min, and enzyme-linked immunosorbent assay instrument measures the UV absorption at each hole 490nm
It is worth (OD value), then calculates cell inhibitory rate, and calculate the IC for finding out compound using linear regression method according to inhibiting rate50Value；
The calculation formula of cell inhibitory rate are as follows:
Inhibiting rate %=(control wells mean OD value-medication group mean OD value)/control wells mean OD value × 100%；
Testing result is shown: compared with negative control group, the class peptides containing alanine are to above-mentioned tumour cell
With different degrees of In-vitro Inhibitory Effect, as shown in table 3.
K562 cell-proliferation activity:
Class peptides of the table 3 containing Terleu are to K562 cell inhibitory rate (%)
From table 3 it can be seen that cell activity screening test shows that compound has certain cell proliferation to K562 cell
Inhibitory activity.Wherein the preferable compound of activity is B5, and inhibiting rate reaches 36.3%.For the class peptides containing Terleu
For closing object, different substituent groups is introduced on pyridine ring, the influence to bioactivity is there are biggish difference, and substituent group
Influence of the position difference to bioactivity is also different.Compound B-11 and B3 are to Bcr-AblT315IThe inhibitory activity of kinases is preferable；Change
It is preferable to the inhibitory activity of K562 cell to close object B5, is worth the further further investigation of expansion.
The present invention is based on to early period Bcr-Abl tyrosine kinase inhibitor and Bcr-Abl albumen and ligand it is mutual
The research such as function analysis, using biphenyl pyridine as hinge area binding fragment, introduces uncle L- using the drug design strategies based on segment
Leucine is flexibility Linker, to construct the class peptides library with kinase inhibiting activity, and the kinases for passing through ADP-Glo
Screening active ingredients are found to have the tyrosine kinase inhibitor of Bcr-Abl kinase inhibiting activity.It is anti-that the compound can be used in preparation
In tumour (chronic myelocytic leukemia) drug, has and inhibit Bcr-Abl, Bcr-AblT315IKinase activity, and it is thin to K562
Born of the same parents have cell proliferation inhibitory activity.Terleu structure is introduced, the various structures of Bcr-Abl kinase inhibitor can be extended
Property, while activity test shows that Terleu Linker plays a significant role the inhibitory activity of compound, can be improved receptor
Affinity between compound can be used as the drug effect segment of Bcr-Abl tyrosine kinase inhibitor.
Claims (10)
1. a kind of class peptides containing Terleu, which is characterized in that the structural formula of such compound is as follows:
Wherein, R is
2. a kind of preparation method of the class peptides containing Terleu as described in claim 1, which is characterized in that packet
Include following steps:
1) the acylated bromo- 2-aminopyridine of 5- of acylation reaction preparation occurs for the bromo- 2-aminopyridine of 5- and chloride compounds；
2)N2Under protection, 5- bromo-nicotinic acid, thionyl chloride and aminated compounds, which react, prepares the 5- bromo-nicotinic acid of ammonification；
3) under tetra-triphenylphosphine palladium catalysis, the 5- bromo-nicotinic acid and right/carboxyl benzene of the bromo- 2-aminopyridine of acylated 5- or ammonification
Suzuki coupling reaction occurs for boric acid, obtains biphenol compound；
4) Fmoc-L- Terleu and the chloro- 3- 5-trifluoromethylaniline condensation of 4- generate (9 fluorenes -9- base) methyl (S)-(1- ((4-
Chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate；
5) (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl-
2- yl) t-butyl carbamate take off Fmoc protecting group generate (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3-
Amide dimethyl butyrate；
6) biphenol compound and the condensation of (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate generate
Class peptides containing Terleu.
3. a kind of preparation method of the class peptides containing Terleu as claimed in claim 2, which is characterized in that institute
Step 1) the detailed process stated are as follows: the bromo- 2-aminopyridine of 5- is dissolved in anhydrous methylene chloride, triethylamine is added, in ice bath item
Under part, be added dropwise chloride compounds, after being added dropwise, remove ice bath be warmed to room temperature reaction 12h after, post-processed, obtain acyl
The bromo- 2-aminopyridine of the 5- of change.
4. a kind of preparation method of the class peptides containing Terleu as claimed in claim 2, which is characterized in that institute
Step 2) the detailed process stated are as follows: in N2Under protection, thionyl chloride is added dropwise in 5- bromo-nicotinic acid, after dripping, is heated back
It flows 2-3h to clarify to solution, decompression rotation removes thionyl chloride, obtains faint yellow solid, which is added to anhydrous dichloro
In methane, in the dichloromethane solution that is then added drop-wise to aminated compounds under condition of ice bath；After dripping, it is warmed to room temperature reaction
12h is post-processed after reaction, obtains the bromo- niacin of 5- of ammonification.
5. a kind of preparation method of the class peptides containing Terleu as claimed in claim 2, which is characterized in that institute
Step 3) the detailed process stated are as follows: the acylated bromo- 2-aminopyridine of 5- and right/Carboxybenzeneboronic acid are added to reaction vessel
In, or the bromo- niacin of the 5- of ammonification and right/Carboxybenzeneboronic acid is added in reaction vessel, sequentially add cesium carbonate and four
Triphenylphosphine palladium；Then the mixed solution of acetonitrile and water, N are added2Protection, is warming up to 90 DEG C of reaction 48h；After reaction,
It is post-processed, obtains biphenol compound.
6. a kind of preparation method of the class peptides containing Terleu as claimed in claim 2, which is characterized in that institute
State the detailed process of step 4) are as follows: the chloro- 3- 5-trifluoromethylaniline of 4-, HOBT, HATU are dissolved in anhydrous methylene chloride, then dripped
Add DIPEA, after being added dropwise, the dichloromethane solution of Fmoc-L- Terleu be added dropwise, reacts at room temperature 5h, is post-processed,
Obtain (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) amino) -3,3- dimethyl -1- oxo butyl- 2-
Base) t-butyl carbamate.
7. a kind of preparation method of the class peptides containing Terleu as claimed in claim 2, which is characterized in that institute
State the detailed process of step 5) are as follows: at 0 DEG C, by (9 fluorenes -9- base) methyl (S)-(1- ((4- chloro- 3- (trifluoromethyl) phenyl) ammonia
Base) -3,3- dimethyl -1- oxo butyl- 2- yl) t-butyl carbamate is dissolved in anhydrous methylene chloride, it is dense that volume is then added dropwise
The DMF solution of 20% piperidines is spent, after reacting 1h, is post-processed, obtains (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) benzene
Base) -3,3- amide dimethyl butyrate.
8. a kind of preparation method of the class peptides containing Terleu as claimed in claim 2, which is characterized in that institute
State the detailed process of step 6) are as follows: biphenol compound, PyBOP are dissolved in anhydrous DMF, DIPEA is added dropwise, reacts at room temperature 5min
Afterwards, (S) -2- amino-N (4- chloro- 3 (trifluoromethyl) phenyl) -3,3- amide dimethyl butyrate is added, 12h is reacted at room temperature, after progress
Processing, obtains the class peptides containing Terleu.
9. a kind of class peptides containing Terleu as described in any one of claim 1-8, which is characterized in that
Such compound is in preparation for inhibiting Abl kinases, T315I to be mutated the application in Abl kinase activity drug.
10. a kind of class peptides containing Terleu as described in any one of claim 1-8, feature exist
In such peptides application in preparation of anti-tumor drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910049053.5A CN109824584B (en) | 2019-01-18 | 2019-01-18 | Tertiary leucine-containing peptoid compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910049053.5A CN109824584B (en) | 2019-01-18 | 2019-01-18 | Tertiary leucine-containing peptoid compound and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109824584A true CN109824584A (en) | 2019-05-31 |
| CN109824584B CN109824584B (en) | 2020-08-18 |
Family
ID=66861712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910049053.5A Active CN109824584B (en) | 2019-01-18 | 2019-01-18 | Tertiary leucine-containing peptoid compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109824584B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040267012A1 (en) * | 2001-10-17 | 2004-12-30 | Angell Richard Martyn | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| CN101223130A (en) * | 2005-07-11 | 2008-07-16 | 惠氏公司 | Glutamate aggrecanase inhibitors |
| CN104262246A (en) * | 2014-08-29 | 2015-01-07 | 西安交通大学 | 5-phenylnicotinamide Bcr-Abl inhibitors as well as preparation method and application thereof |
| CN104262244A (en) * | 2014-08-29 | 2015-01-07 | 西安交通大学 | 5-phenylpyridine-2-amine Bcr-Abl inhibitors as well as preparation method and application thereof |
-
2019
- 2019-01-18 CN CN201910049053.5A patent/CN109824584B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040267012A1 (en) * | 2001-10-17 | 2004-12-30 | Angell Richard Martyn | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| CN101223130A (en) * | 2005-07-11 | 2008-07-16 | 惠氏公司 | Glutamate aggrecanase inhibitors |
| CN104262246A (en) * | 2014-08-29 | 2015-01-07 | 西安交通大学 | 5-phenylnicotinamide Bcr-Abl inhibitors as well as preparation method and application thereof |
| CN104262244A (en) * | 2014-08-29 | 2015-01-07 | 西安交通大学 | 5-phenylpyridine-2-amine Bcr-Abl inhibitors as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| AGNIESZKA CHOLEWIAK ET AL.: "Disulphide bond exchange inhibited by air-kinetic and thermodynamic products in a library of macrocyclic cysteine derivatives", 《ORG. BIOMOL. CHEM.》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109824584B (en) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2671354T3 (en) | DNA-PK inhibitors | |
| Yang et al. | Synthesis, biological evaluation, and molecular docking studies of 1, 3, 4-thiadiazol-2-amide derivatives as novel anticancer agents | |
| CA2908098A1 (en) | Mk2 inhibitors and uses thereof | |
| CN109796439B (en) | Hydroxyproline peptide derivative and preparation method and application thereof | |
| NZ525324A (en) | Nitrogenous aromatic ring compounds | |
| AU2018286221B2 (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
| Ma et al. | Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening | |
| CN108239083A (en) | Aryl hydrocarbon receptor conditioning agent | |
| CN102933578A (en) | Cyanoquinoline derivatives | |
| CN105705493A (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
| Canale et al. | Solid-supported synthesis, molecular modeling, and biological activity of long-chain arylpiperazine derivatives with cyclic amino acid amide fragments as 5-HT7 and 5-HT1A receptor ligands | |
| Zhao et al. | Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors | |
| CN110078708A (en) | Smo inhibitor and its synthetic method and application | |
| Hamdi et al. | Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: Molecular modeling studies | |
| Zhang et al. | Design, synthesis and biological evaluation of KRASG12C-PROTACs | |
| CN104910894B (en) | Benzimidazole hERG potassium ion channel small-molecular fluorescent probe and preparation method and applications thereof | |
| CN114437113B (en) | Thiazolopyridine cyclotriazole compound, and preparation method and application thereof | |
| CN109824584A (en) | A kind of class peptides and its preparation method and application containing Terleu | |
| Fang et al. | Design, synthesis and biological evaluation of E-ring modified evodiamine derivatives as novel antitumor agents | |
| CN109761957B (en) | Hydroxyproline-containing compound and preparation method and application thereof | |
| CN109824581A (en) | A kind of class peptides containing alanine with and its preparation method and application | |
| CN107163028B (en) | A kind of benzamides Hedgehog inhibitor and its preparation method and application | |
| Ilić et al. | Fluorinated dual antithrombotic compounds based on 1, 4-benzoxazine scaffold | |
| CN109651243A (en) | A kind of class peptides and its preparation method and application containing serine | |
| CN106543194A (en) | Narciclasine derivative and its preparation and the application in antineoplastic is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |